Abstract
The “off label” use of rhBMP-2 in the transforaminal lumbar interbody fusion (TLIF) procedure has become increasingly popular. Although several studies have demonstrated the successful use of rhBMP-2 for this indication, uncertainties remain regarding its safety and efficacy. The purpose of this study is to evaluate the clinical and radiographic outcomes of the single-level TLIF procedure using rhBMP-2. Patients who underwent a single-level TLIF between January 2004 and May 2006 with rhBMP-2 were identified. A retrospective evaluation of these patients included operative report(s), pre- and postoperative medical records, and dynamic and static lumbar radiographs. Patient-reported clinical outcome measures were obtained from a telephone questionnaire and included a modification of the Odom’s criteria, a patient satisfaction score, and back and leg pain numeric rating scale scores. Forty-eight patients met the study criteria and were available for follow-up (avg. radiographic and clinical follow-up of 19.4 and 27.4 months, respectively). Radiographic fusion was achieved in 95.8% of patients. Good to excellent results were achieved in 71% of patients. On most recent clinical follow-up, 83% of patients reported improvement in their symptoms and 84% reported satisfaction with their surgery. Twenty-nine patients (60.4%) reported that they still had some back pain, with an average back pain numeric rating score of 2.8. Twenty patients (41.7%) reported that they still had some leg pain, with an average leg pain numeric rating score was 2.4. Thirteen patients (27.1%) had one or more complications, including transient postoperative radiculitis (8/48), vertebral osteolysis (3/48), nonunion (2/48), and symptomatic ectopic bone formation (1/48). The use of rhBMP-2 in the TLIF procedure produces a high rate of fusion, symptomatic improvement and patient satisfaction. Although its use eliminates the risk of harvesting autograft, rhBMP-2 is associated with other complications that raise concern, including a high rate of postoperative radiculitis.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Boden SD, Kang J, Sandhu H et al (2002) Use of recombinant human bone morphogenetic protein-2 to achieve posterolateral lumbar spine fusion in humans: a prospective, randomized clinical pilot trial: 2002 Volvo Award in clinical studies. Spine 27:2662–2673. doi:10.1097/00007632-200212010-00005
Burkus JK, Dorchak JD, Sanders DL (2003) Radiographic assessment of interbody fusion using recombinant human bone morphogenetic protein type 2. Spine 28:372–377. doi:10.1097/00007632-200302150-00012
Burkus JK, Sandhu HS, Gornet MF (2006) Influence of rhBMP-2 on the healing patterns associated with allograft interbody constructs in comparison with autograft. Spine 31:775–781. doi:10.1097/01.brs.0000206357.88287.5a
Copay AG, Glassman SD, Subach BR et al (2008) The minimum clinically important difference in lumbar spine surgery patients: a choice of methods using the Oswestry disability index, Medical Outcomes Study questionnaire Short Form 36, and Pain Scales. Spine J 8(6):968–974
Epstein NE (2006) A preliminary study of the efficacy of beta tricalcium phosphate as a bone expander for instrumented posterolateral lumbar fusions. J Spinal Disord Tech 19:424–429. doi:10.1097/00024720-200608000-00009
Epstein NE (2008) An analysis of noninstrumented posterolateral lumbar fusions performed in predominantly geriatric patients using lamina autograft and beta tricalcium phosphate. Spine J 8(6):882–887
Fernyhough JC, Schimandle JJ, Weigel MC et al (1992) Chronic donor site pain complicating bone graft harvesting from the posterior iliac crest for spinal fusion. Spine 17:1474–1480
Glassman SD, Dimar JR 3rd, Burkus K et al (2007) The efficacy of rhBMP-2 for posterolateral lumbar fusion in smokers. Spine 32:1693–1698. doi:10.1097/BRS.0b013e318074c366
Goulet JA, Senunas LE, DeSilva GL et al (1997) Autogenous iliac crest bone graft. Complications and functional assessment. Clin Orthop Relat Res 1997:76–81. doi:10.1097/00003086-199706000-00011
Haid RW Jr, Branch CL Jr, Alexander JT et al (2004) Posterior lumbar interbody fusion using recombinant human bone morphogenetic protein type 2 with cylindrical interbody cages. Spine J 4:527–538. doi:10.1016/j.spinee.2004.03.025 (discussion 38–39)
Harms JG, Jeszenszky D (1998) Oper Orthop Traumatol 10:90–102. doi:10.1007/s00064-006-0112-7
Harms J, Rolinger H (1982) A one-stager procedure in operative treatment of spondylolistheses: dorsal traction-reposition and anterior fusion (author’s transl). Z Orthop Ihre Grenzgeb 120:343–347. doi:10.1055/s-2008-1051624
Hudak PL, Wright JG (2000) The characteristics of patient satisfaction measures. Spine 25:3167–3177. doi:10.1097/00007632-200012150-00012
Joseph V, Rampersaud YR (2007) Heterotopic bone formation with the use of rhBMP2 in posterior minimal access interbody fusion: a CT analysis. Spine 32:2885–2890
Lewandrowski KU, Nanson C, Calderon R (2007) Vertebral osteolysis after posterior interbody lumbar fusion with recombinant human bone morphogenetic protein 2: a report of five cases. Spine J 7:609–614. doi:10.1016/j.spinee.2007.01.011
Lowe TG, Tahernia AD, O’Brien MF et al (2002) Unilateral transforaminal posterior lumbar interbody fusion (TLIF): indications, technique, and 2-year results. J Spinal Disord Tech 15:31–38
Mummaneni PV, Pan J, Haid RW et al (2004) Contribution of recombinant human bone morphogenetic protein-2 to the rapid creation of interbody fusion when used in transforaminal lumbar interbody fusion: a preliminary report. Invited submission from the Joint Section Meeting on Disorders of the Spine and Peripheral Nerves, March 2004. J Neurosurg Spine 1:19–23
Odom GL, Finney W, Woodhall B (1958) Cervical disk lesions. J Am Med Assoc 166:23–28
Potter BK, Freedman BA, Verwiebe EG et al (2005) Transforaminal lumbar interbody fusion: clinical and radiographic results and complications in 100 consecutive patients. J Spinal Disord Tech 18(4):337–346
Sawin PD, Traynelis VC, Menezes AH (1998) A comparative analysis of fusion rates and donor-site morbidity for autogeneic rib and iliac crest bone grafts in posterior cervical fusions. J Neurosurg 88:255–265
Schwender JD, Holly LT, Rouben DP et al (2005) Minimally invasive transforaminal lumbar interbody fusion (TLIF): technical feasibility and initial results. J Spinal Disord Tech 18:S1–S6. doi:10.1097/01.bsd.0000132291.50455.d0
Villavicencio AT, Burneikiene S, Nelson EL et al (2005) Safety of transforaminal lumbar interbody fusion and intervertebral recombinant human bone morphogenetic protein-2. J Neurosurg Spine 3:436–443
Ware JE Jr, Hays RD (1988) Methods for measuring patient satisfaction with specific medical encounters. Med Care 26:393–402. doi:10.1097/00005650-198804000-00008
Wong DA, Kumar A, Jatana S et al (2008) Neurologic impairment from ectopic bone in the lumbar canal: a potential complication of off-label PLIF/TLIF use of bone morphogenetic protein-2 (BMP-2). Spine J 8(6):1011–1018
Yamashita K, Ohzono K, Hiroshima K (2006) Patient satisfaction as an outcome measure after surgical treatment for lumbar spinal stenosis: testing the validity and discriminative ability in terms of symptoms and functional status. Spine 31:2602–2608. doi:10.1097/01.brs.0000240717.25787.7d
Acknowledgments
No sources of funding were used to perform this study.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Rihn, J.A., Makda, J., Hong, J. et al. The use of RhBMP-2 in single-level transforaminal lumbar interbody fusion: a clinical and radiographic analysis. Eur Spine J 18, 1629–1636 (2009). https://doi.org/10.1007/s00586-009-1046-1
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00586-009-1046-1